Acceleron Pharma's loss under GAAP for 6 months of 2020 was $69,391 million, up 24.1% from $55,913 million the previous year. Revenue increased by 44.8% to $44,096 million compared to $30,447 million a year earlier.
Acceleron Pharma's loss under GAAP for 6 months of 2020 was $69,391 million, up 24.1% from $55,913 million the previous year. Revenue increased by 44.8% to $44,096 million compared to $30,447 million a year earlier. 
investor.acceleronpharma.com
English (US) 